Table 2. Comparison of the efficacy for the 2 groups.

Intracranial outcome	Pyrotinib + radiotherapy (N=35)	Pyrotinib (N=44)	P value
CR	2 (5.7%)	0
PR	15 (42.9%)	9 (20.5%)
SD	12 (34.3%)	25 (56.8%)
SD ≥6 months	11 (31.4%)	22 (50.0%)
PD	6 (17.1%)	10 (22.7%)
ORR	48.6% (17/35)	20.5% (9/44)	0.015
CBR	80.0% (28/35)	70.5% (31/44)	0.308

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; CBR, clinical benefit rate.